Abstract
Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. Representatives of ruthenium-based antitumor drugs are the classes of ruthenium(III)-chlorido-(N-ligand) complexes, including the drugs namely NAMI-A and KP1019 in clinical trials, and ruthenium(II)-arene organometallics, with some compounds currently undergoing advanced preclinical testing. An alternative approach for tumor-inhibiting metallodrugs is the coordination of metal ions to organic pharmaceuticals. The combination of antitumor-active ruthenium ion with biologically-active pro-ligands in single compounds can result in the enhancement of activity, for example through synergistic effects. In the present article, some developments in the ruthenium-based antitumor drugs field are briefly highlighted and recent studies on mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy are described. Novel organic pharmaceuticals-containing diruthenium(II,III) complexes have shown promising antitumor activity for C6 rat glioma - a model for glioblastoma multiforme (GBA).
Keywords: Anticancer activity, antitumor metallodrugs, coordination compounds, glioma, medicinal chemistry, non-steroidal antiinflammatory drugs, ruthenium compounds
Anti-Cancer Agents in Medicinal Chemistry
Title: Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Volume: 10 Issue: 4
Author(s): Denise de Oliveira Silva
Affiliation:
Keywords: Anticancer activity, antitumor metallodrugs, coordination compounds, glioma, medicinal chemistry, non-steroidal antiinflammatory drugs, ruthenium compounds
Abstract: Ruthenium compounds have been actively studied as metallodrugs for cancer therapy. Representatives of ruthenium-based antitumor drugs are the classes of ruthenium(III)-chlorido-(N-ligand) complexes, including the drugs namely NAMI-A and KP1019 in clinical trials, and ruthenium(II)-arene organometallics, with some compounds currently undergoing advanced preclinical testing. An alternative approach for tumor-inhibiting metallodrugs is the coordination of metal ions to organic pharmaceuticals. The combination of antitumor-active ruthenium ion with biologically-active pro-ligands in single compounds can result in the enhancement of activity, for example through synergistic effects. In the present article, some developments in the ruthenium-based antitumor drugs field are briefly highlighted and recent studies on mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy are described. Novel organic pharmaceuticals-containing diruthenium(II,III) complexes have shown promising antitumor activity for C6 rat glioma - a model for glioblastoma multiforme (GBA).
Export Options
About this article
Cite this article as:
de Oliveira Silva Denise, Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2010; 10 (4) . https://dx.doi.org/10.2174/187152010791162333
DOI https://dx.doi.org/10.2174/187152010791162333 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Neovascularization and Proinflammatory Microenvironments
Current Cancer Drug Targets Towards the Development of Tumor Necrosis Factor (TNF) Sensitizers:Making TNF Work Against Cancer
Current Pharmaceutical Design Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism Advanced Neuroimaging Techniques in the Management of Glioblastoma Multiforme
Current Radiopharmaceuticals Pharmacokinetics of Polymeric Micelles for Cancer Treatment
Current Drug Metabolism Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology A Comprehensive Insight Towards Pharmaceutical Aspects of Graphene Nanosheets
Current Pharmaceutical Biotechnology Doxycycline as Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy and Cell Reprogramming For the Aging Brain: Achievements and Promise
Current Gene Therapy EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy Review of Procedures Used for the Extraction of Anti-Cancer Compounds from Tropical Plants
Anti-Cancer Agents in Medicinal Chemistry Aggrecanase: The Family and Its Inhibitors
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nanobiotechnology-based Drug Delivery in Brain Targeting
Current Pharmaceutical Biotechnology MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Pro-Inflammatory Cytokines and their Actions on the Metabolic Disturbances Associated with Cancer: Implications in Cachexia
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature
Current Drug Targets Optical Image-Guided Cancer Therapy
Current Pharmaceutical Biotechnology Role of Graphene Nano-Composites in Cancer Therapy: Theranostic Applications, Metabolic Fate and Toxicity Issues
Current Drug Metabolism <sup>177</sup>Lu-Labeled Agents for Neuroendocrine Tumor Therapy and Bone Pain Palliation in Uruguay
Current Radiopharmaceuticals Stimuli-Responsive Nanocarriers for Drug Delivery to the Central Nervous System
Current Nanoscience